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Epidemiology is the study of the patterns and determi-
nants of health-related events and the application of this
knowledge to the control of disease. It is important in
understanding disease incidence and helpful for the dis-
covery of disease risk factors. Sarcomas are rare and het-
erogeneous and, as such, pose significant challenges
epidemiologically. In most parts of the world, sarcomas
are estimated to account for 1-3% of all cancers. More-
over, sarcomas comprise over 50 different histological
subtypes, which are being reclassified continually, as new
entities are defined with new technologies and new clas-
sifications. Sarcoma subtypes range from diseases that
arise in a putative stem cell-like population (primitive
neuroectodermal tumors) to those arising from morpho-
logically recognisable connective tissues such as bone, fat
and cartilage. The outcomes for patients with sarcomas
are equally heterogeneous. Taking all of the subtypes to-
gether, sarcomas collectively meet the US Rare Diseases
Act (2002) definition of any condition that affects fewer
than 200,000 people by some margin. The peculiarities of
the epidemiology of sarcoma are outlined in this series
by Burningham et al. [1].
Readers of this series will be struck by the degree to
which familial sarcoma syndromes have broadly contrib-
uted to understanding of cancer biology, including the
fundamentals of cell cycle regulation and maintenance of
the genome integrity. For example, sarcomas comprise
the single most common cancer type seen in families
with Li-Fraumeni syndrome, which is most commonly
caused by germline mutations in TP53. The study of
TP53 biology in sarcomas has contributed to our know-
ledge of this crucial tumour suppressor that is the most
somatically mutated gene in human cancers. The story of
p53 demonstrates the contribution of mouse models of
human disease (see papers by Ng et al. [2]; and Post [3]).
Individuals with retinoblastoma, an inherited cancer syn-
drome, have a 500-fold increased incidence of bone sar-
comas, predominately osteosarcoma (reviewed here by
Kleinerman et al. [4]). Long before the gene responsible
for this syndrome (RB1) was identified, epidemiologic
studies of affected families led to the ‘two-hit’ hypothesis
of tumor suppressor genes [5]. Other important exam-
ples of the hereditary sarcomas described in this series
include gastrointestinal stromal tumors [6] and malig-
nant peripheral nerve sheath tumors [7].
Despite (or perhaps because of ) being rare, sarcomas
have acted as sentinel events that are epidemiologically
noteworthy. While it is sometimes difficult to distinguish
sporadic from hereditary breast cancer, a sarcoma occur-
ring twice within the one family is epidemiologically
striking. Another feature of sarcomas is the relatively
young age of onset. Cancer is generally a disease of age-
ing: the average age of cancer diagnosis in Western
countries is in the late 60s. By contrast, sarcomas affect
younger populations, while some sarcomas (primarily
rhabdomyosarcoma, osteosarcoma, and Ewing sarcoma)
are essentially diseases of childhood and adolescence.
Epidemiologically, early onset cancer usually suggests
predisposing factors are at play, whether environmental
or hereditary. Environmental causes of sarcoma are less
well defined, but an obvious example is the carcinogenic
effects of ionising radiation (see review by Berrington de
Gonzalez et al. [8]). Other potential environmental carci-
nogens, such as herbicides, polyvinyl chloride, arsenicals,
have been linked to sarcoma incidence.
Cancer is fundamentally a genetic disease. While
genome-wide expression, miRNA and copy number
technologies have improved disease classification, novel
sequencing approaches are likely to reform our under-
standing of the germline and somatic causes of cancer.
These advances have the potential to better apply tar-
geted therapies, thus further “personalizing” cancer ther-
apy. Many somatic mutations will be ‘actionable’, a term
used to define a known link between the mutation and
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response (or not) to the increasing range of targeted and
re-purposed therapies available in the clinic. Sarcomas
such as gastrointestinal stromal tumor and dermatofibro-
sarcoma protuberans demonstrate the power of linking
genetic mutations to effective targeted therapy. While
such therapeutic opportunities are immensely exciting,
in general they turn cancer from an inexorably lethal
disease into a chronic (and socially expensive) condition.
For most cancers, and especially for sarcomas, surgery
remains critical to cure. However, once disseminated,
surgery has a limited role to play in achieving cure. De-
tection of cancers at an early stage, prior to spread, is es-
sential to enable effective surgery. Arguably therefore,
the most effective mechanism for improved survival lies
in prevention and early detection. This has already been
demonstrated by the application of screening procedures
in populations affected by lung, bowel and breast can-
cers [9]. Screening for sarcomas is not feasible in the
general population due to their rarity. In certain familial
cancer syndromes, such as Li-Fraumeni syndrome or
Rothmund Thomson syndrome, where there is a high
risk of sarcoma, this may be warranted, although further
studies of the impact on clinical outcomes are needed.
The cost and benefit of screening is therefore opti-
mised if they are applied to high-risk populations—which
is where the genomic revolution comes in. Let us take
breast and ovarian cancer as the best-studied basis for
estimates of heritable cancer risk. Using family history
alone, it is estimated that only about 5-10% of cancer has
a hereditary component. Moreover, in only about half of
these cases has a genetic basis been identified, usually by
serially assaying for likely causal genes (eg, mutations in
BRCA1 or BRCA2 in families with lots of breast cancer).
Typically, once a mutation is identified, no further testing
is applied, because it is assumed that a single mutation
underlies the familial predisposition. This approach has
been used to generate estimates of the likely penetrance
(and therefore clinical significance) of the linked muta-
tion. By definition, de novo mutations will not be identi-
fied using familial pedigree as a screening tool, even
though the clinical significance of the mutation for the
affected individual and their progeny may be identical to
that of an individual who inherits the same mutation
from a parent.
It is highly likely that this paradigm will shift dramatic-
ally in the coming years. A recent study by Walsh and
colleagues [10] applied massively parallel sequencing of
21 genes in a population of 360 patients with ovarian,
peritoneal and fallopian tube cancers—unselected for
family or personal history of cancer. The genes were
chosen because they had been linked previously to can-
cer predisposition. Remarkably 82 of the 360 (24%) car-
ried 85 pathogenic mutations in their germline. These
mutations were identified as unambiguously of clinical
importance. Moreover, 3 (4%) carried two such muta-
tions. In many cases, the mutations were identified in
individuals who had no family or personal history of
cancer, consistent with either a striking de novo muta-
tion rate or differences in penetrance in this cohort.
Taken together, studies such as this suggest that the sys-
tematic application of massively parallel sequencing to
populations with sarcoma will identify a very significant
proportion who are at significantly greater risk for sec-
ond cancers, or who may pass on the mutation to their
offspring. In some cases, the mutation may affect the
choice of therapy for the primary cancer. Clinicians may
elect, for example, to avoid carcinogenic therapies in
individuals carrying mutations in DNA repair genes.
This brings us back to the epidemiology of sarcomas,
our understanding of their multi-factorial etiologies, and
the future for our patients with these cancers. In the
coming years, deep sequencing technologies may make
the complex outbred genetics of human populations a
tractable system to complement animal models. The ap-
plication of new genetic tools may not only result in re-
classification of sarcoma, but may also systematically
identify people who carry germline and/or somatic muta-
tions in cancer-causing genes. Because each cancer seems
to have its own spectrum of mutations, the study of sar-
comas may shed interesting light on the biology of cancer
in general, above that which will be had from sequencing
more common cancer types through global enterprises
such as the International Cancer Genome Consortium.
Because sarcomas affect a younger population, with a
higher rate of known familial syndromes, it is also likely
that systematic studies such as that by Walsh et al. [10]
will identify a significant proportion of individuals who
carry mutations in new or known ‘sarcoma genes’. The
ultimate goal of epidemiology is to enable improvements
in cancer outcomes. The identification of high-risk will
form an essential component of screening and preven-
tion strategies, can be used to facilitate reproductive de-
cision making in a young population, and may affect
treatment choices directly. The implications are broad,
and go beyond simply identifying that risk: but it’s a start.
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